Difference between revisions of "Aripiprazole"

(Administration: added dosage forms)
Line 51: Line 51:
[[Category:Pharmacology]] [[Category:Psychiatry]]

Latest revision as of 20:15, 19 September 2019


  • Type: Atypical antipsychotic
  • Dosage Forms: tablet, oral disintegrating tablet, oral solution, extended-release injectable IM suspension
  • Routes of Administration: PO, IM depot
  • Common Trade Names: Abilify, Maintena, Aristada

Adult Dosing

  • 2-30 mg PO daily

Pediatric Dosing

  • > 6yo: 2-30 mg PO daily (slower titration up)

Special Populations

  • Pregnancy Rating: C
  • Lactation risk: Infant risk cannot be ruled out
  • Concomitant use of CYP3A4 or CYP2D6 inhibitors: reduce dose
  • Concomitant use of CYP3A4 inducers: increase dose
  • Renal dosing: no adjustment
  • Hepatic dosing: no adjustment


  • Allergy to class/drug

Adverse Reactions


  • Cardiac arrest, cardiac failure, prolonged QT, MI
  • Neuroleptic malignant syndrome, hyperthermia, rhabdomyolysis
  • Seizure, stroke
  • Tardive dyskinesia
  • Agranulocytosis, leukopenia
  • Angioedema
  • Pancreatitis
  • DKA
  • Suicidal behavior


  • Somnolence, dizziness, akathisia, anxiety, insomnia, headache
  • Extrapyramidal symptoms, tremor
  • Nausea, vomiting, constipation
  • Weight gain


  • Half-life: ~75 hours
  • Metabolism: Hepatic via CYP2D6 and CYP3A4
  • Excretion: Mostly fecal

Mechanism of Action

  • Not well understood. D2 and HT2A antagonist, D3 and 5HT1A partial agonist


See Also